Phase 1/2Terminated
Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors (ATTACC)
Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC)
- Sponsor
- Repare Therapeutics (Industry)
- Enrollment
- 156 enrolled
- Conditions
- Advanced Solid Tumor, Adult
- Interventions
- RP-3500 (camonsertib)
- Ages
- adults, older adults
- Registry
- NCT04972110
Full record on ClinicalTrials.gov
From the registry
The primary purpose of this study is to assess the safety and tolerability of niraparib or olaparib in combination with RP-3500 (camonsertib), in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-3500 (camonsertib) in combination with niraparib or olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity.
Primary outcomes
- Determine the Safety and Tolerability of Niraparib or Olaparib in Combination With RP-3500 in Patients With Molecularly Selected Solid Tumors
- Define the Recommended Phase 2 Dose (RP2D) of RP-3500 in Combination With Niraparib or Olaparib in Patients With Molecularly Selected Solid Tumors
History
Results first posted
Last registry update
Primary completion
Registered
Started